Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C] SY-5007 in Healthy Males
NCT06352190Phase 1Not yet recruiting
- Sponsor
- Shouyao Holdings
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotetinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and Papillary Thyroid Cancer (PTC), sponsored by Shouyao Holdings. Primary endpoints: Maximum Plasma Concentration of Total Radioactivity, Time to Maximum Plasma Concentration of Total Radioactivity and 6 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
sotetinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)Papillary Thyroid Cancer (PTC)
Beyond the preview
Go deeper on NCT06352190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352190.